Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug

Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug

Abstract New strategies to decrease risk of relapse after surgery are needed for improving 5‐year survival rate of hepatocellular carcinoma (HCC). To address this need, a wound‐targeted nanodrug is developed, that contains an immune checkpoint inhibitor (anti‐PD‐L1)and an angiogenesis inhibitor (sor...

Full description

Bibliographic Details
Main Authors: Bozhao li, Xiuping Zhang, Zhouliang Wu, Tianjiao Chu, Zhenlin Yang, Shuai Xu, Suying Wu, Yunkai Qie, Zefang Lu, Feilong Qi, Minggen Hu, Guodong Zhao, Jingyan Wei, Yuliang Zhao, Guangjun Nie, Huan Meng, Rong Liu, Suping Li
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:Advanced Science
Subjects:
combination therapy
hepatocellular carcinoma recurrence
mesoporous silica nanoparticle
platelet membrane
Online Access:https://doi.org/10.1002/advs.202200477

Internet

https://doi.org/10.1002/advs.202200477

Similar Items